STG 001
Alternative Names: STG-001Latest Information Update: 28 Jul 2022
At a glance
- Originator Stargazer Pharmaceuticals
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Stargardt disease
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for phase-I development in Stargardt disease(In volunteers, In adults) in Australia (PO, Capsule)
- 24 Apr 2021 Stargazer Pharmaceuticals completes a phase IIa trial in Stargardt Disease in USA (PO) (NCT04489511)
- 01 Oct 2020 Phase-II clinical trials in Stargardt disease in USA (PO) (NCT04489511)